Impetigo R&D Pipeline Analysis Report, Q4 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Impetigo R&D Pipeline Analysis Report, Q4 2020” report has been added to ResearchAndMarkets.com’s offering.

This quarterly review describes the pipeline of drugs under development for Impetigo, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Impetigo Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Impetigo disease overview, Impetigo types, Impetigo symptoms, causes, and FDA/EMA approved treatment options.

Impetigo Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Impetigo indication. The report presents near-term and long-term pipeline development trends and potential insights.

Impetigo Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 6 companies. Business profiles and contact details of the companies actively perusing Impetigo pipeline are assessed.

Impetigo R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Impetigo discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

(Read more…)

Small Impetigo companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Impetigo pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Impetigo Pipeline Market News and Developments during 2020

The Impetigo industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Impetigo Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage

• Impetigo pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
• Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
• Company-company partnerships, company-institute partnerships, and investment details of companies are included
• 6 companies are included including FUJIFILM Toyama Chemical Co Ltd, Laboratories Ojer Pharma SL, Lipidor AB, Next Science Ltd, SutroVax Inc, UNION Therapeutics,
• Disease overview, Pipeline trends, market analysis, and other developments
• Potential licensing/new business opportunities in Impetigo pipeline market

Highlights

• Global coverage of companies and pipeline agents
• 2020 Trends, market analysis, and developments
• Potential growth opportunities
• Comprehensive details of drug candidates

Reasons to Buy

• Drive pipeline research and commercial assessment
• Assess most promising drug candidates and stay ahead of the competition
• Strengthen your pipeline through identifying business expansion and acquisition opportunities
• Develop new candidates based on most focused targets and mechanism of actions

Companies Mentioned

• FUJIFILM Toyama Chemical Co Ltd
• Laboratories Ojer Pharma SL
• Lipidor AB
• Next Science Ltd
• SutroVax Inc
• UNION Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/3db4we

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900